AUTHOR=Heck Julia E., Moore Lee , Lee Yuan-Chin Amy , McKay James , Hung Rayjean , Karami Sara , Gaborieau Valérie , Szeszenia-Dabrowska Neonila , Zaridze David , Mukeriya Anush , Mates Dana , Foretova Lenka , Janout Vladimir , Kollárová Helena , Bencko Vladimir , Rothman Nathaniel , Brennan Paul , Chow Wong-Ho , Boffetta Paolo 

TITLE=Xenobiotic Metabolizing Gene Variants and Renal Cell Cancer: A Multicenter Study

JOURNAL=Frontiers in Oncology

VOLUME=2

YEAR=2012

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2012.00016

DOI=10.3389/fonc.2012.00016

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> The countries of Central and Eastern Europe have among the highest worldwide rates of renal cell cancer (RCC). Few studies have examined whether genetic variation in xenobiotic metabolic pathway genes may modify risk for this cancer. <bold>Methods:</bold> The Central and Eastern Europe Renal Cell Cancer study was a hospital-based case–control study conducted between 1998 and 2003 across seven centers in Central and Eastern Europe. Detailed data were collected from 874 cases and 2053 controls on demographics, work history, and occupational exposure to chemical agents. Genes [cytochrome P-450 family, <italic>N</italic>-acetyltransferases, NAD(P)H:quinone oxidoreductase I (<italic>NQO1</italic>), microsomal epoxide hydrolase (<italic>mEH</italic>), catechol-<italic>O</italic>-methyltransferase (<italic>COMT</italic>), uridine diphosphate-glucuronosyltransferase (<italic>UGT</italic>)] were selected for the present analysis based on their putative role in xenobiotic metabolism. Haplotypes were calculated using fastPhase. Odds ratios and 95% confidence intervals were estimated by unconditional logistic regression adjusted for country of residence, age, sex, smoking, alcohol intake, obesity, and hypertension. <bold>Results:</bold> We observed an increased risk of RCC with one SNP. After adjustment for multiple comparisons it did not remain significant. Neither <italic>NAT1</italic> nor <italic>NAT2</italic> slow acetylation was associated with disease. <bold>Conclusion:</bold> We observed no association between this pathway and renal cell cancer.</p>